Imperial Innovations Group Regulatory News (IVO)

2 Nov 2006 08:00

Imperial Innovations Group plc02 November 2006 Imperial Innovations Group plc £7 million Imperial BioIncubator in South Kensington now Operational Imperial Innovations Group plc ("Imperial Innovations", AIM: IVO), thetechnology commercialisation and investment company, announces that the ImperialBioIncubator is now complete and operational as viewed by attendees at theImperial Innovations Spin-out Forum yesterday evening. The BioIncubator is acustom-designed facility which will provide office and laboratory space for upto 15 early-stage companies. Conveniently located on the South Kensington campus of Imperial College incentral London, the BioIncubator aims to accelerate the development of ImperialInnovations spin-out companies by providing a physical centre for the incubationand development programmes of Imperial Innovations. The two-storey, 24,000square foot building was jointly funded with £4 million from Imperial Collegeand £3 million from the London Development Agency (LDA). The BioIncubator consists of 12 wet laboratories, 16 private offices and a suiteof meeting rooms and provides the tenants with a range of research resources andbusiness and support services. Imperial Innovations, which is responsible forthe operation and management of the BioIncubator, will continue to providecompanies with strategic, management and mentoring advice. The following Imperial Innovations companies have already relocated to theImperial BioIncubator: - Advanced Tissue Therapies Limited - Circassia Holdings Limited - deltaDOT Limited - Hydroventuri Limited - Midaz Lasers Limited - Molecular Vision Limited - Nexeon Limited - Thiakis Limited A further five companies will be moving into the Imperial BioIncubator shortly. Susan Searle, CEO of Imperial Innovations said: "I am delighted that the Imperial BioIncubator is now home to so many of ourspin-out companies and to see them taking advantage of the purpose-built spaceand research resources. This excellent facility will not only make operationseasier for our spin-out companies, but will also see them placed to benefit fromday-to-day interaction with Imperial College academics. Coupled with ourincubation and investment programmes, the BioIncubator will no doubt speed upthe development of the spin-outs housed there." Tony Baxter, CEO of deltaDOT said: "As one of the occupants of the Imperial BioIncubator deltaDOT is grateful toImperial College and the LDA for providing the funding for this excellentfacility. It meets our needs from both commercial and research perspectives. Itis immensely important for deltaDOT to remain close to the resources and ongoingsupport of Imperial Innovations who are also situated on the Imperial Collegecampus and to be centrally located where customers can easily reach us." - Ends - For more information contact: Imperial InnovationsLucy Ahfong, Marketing Officer +44 (0)20 7594 6644 M:CommunicationsPatrick d'Ancona / Eleanor Williamson +44 (0)20 7153 1539 Notes to Editors Imperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment in spin-outcompanies. A wide range of technologies are commercialised within the areas ofhealthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in58 spin-out companies and has completed 90 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations. Imperial Innovations has invested in a range of spin-out companies including TheAcrobot Company Limited, Cardiak Limited, deltaDOT Limited, Future Waves PTELimited, HeliSwirl Technologies Limited, InforSense Limited, Lontra Limited,Midaz Lasers Limited, NanoBioDesign Limited, Nexeon Limited, NovaThera Limited,Photobiotics Limited, Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in three spin-out companies nowlisted on AIM; fuel cell company, Ceres Power plc, and ParOS plc, a provider ofenergy-saving advanced control solutions, as well as Nanoscience plc, adeveloper of low power integrated circuits and silicon chips, following itsacquisition of spin-out company Toumaz Technology Limited. Website: www.imperialinnovations.co.uk About the companies located in the BioIncubator - Advanced Tissue Therapies Limited is a biomaterials company withproprietary technologies for the development of tissue engineering productsaimed initially at orthopaedic and maxillofacial markets. - Circassia Limited is developing a way of using peptides as a vaccineagainst allergies. - deltaDOT Limited's core technology allows the direct monitoring ofunlabelled bio-molecules in real time. - Hydroventuri Limited is a renewable energy and hydro services company,which is developing technology to extract energy from tidal streams and riverswith no moving parts in water. - Midaz Laser Limited is developing a new high power DPSS (diode-pumpedsolid state) laser, with advanced coupling and thermal management. - Molecular Vision Limited has invented a novel method for opticaldetection that is fully compatible with microfluidic chip technology. - Nexeon Limited is refining novel battery technology that it predictswill enable greater energy storage. - Thiakis Limited is a privately owned biopharmaceutical company foundedin 2004, focused on the development of novel therapeutic approaches for thetreatment of obesity and other metabolic diseases. This information is provided by RNS The company news service from the London Stock Exchange